BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Luminex Corporation (LMNX) Announces Finalization of the Purchase Price Allocation Related to Tm Bioscience Corporation (CV:TMC) Acquisition


11/12/2007 2:28:19 PM

AUSTIN, Texas--(BUSINESS WIRE)--Luminex Corporation (NASDAQ:LMNX) today announced that it had completed its allocation of the purchase price related to the acquisition of Tm Bioscience completed on March 1, 2007. As previously disclosed, Luminex had completed a preliminary valuation of acquired intangible assets and recorded $30.8 million of goodwill related to the Tm Bioscience acquisition. As of this week, Luminex finalized its valuation analysis, and consequently, the goodwill balance has been increased to $39.6 million and a total of $26.2 million has been allocated to identified acquired intangible assets of which $7.4 million represents in-process research and development. The final valuation analysis identified a decrease in the fair value of the long-term debt of $1.1 million. Accordingly, financial information for the third quarter and nine months ended September 30, 2007, previously released on October 24, 2007, has been revised to reflect the purchase price adjustments and are included in this press release and supercede the financial information previously released and filed with a current report on Form 8-K.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES